Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients
Authors:
- Kimberly R. Jacob ArriolaKAKimberly R. Jacob Arriola
- Kandra HorneKHKandra Horne
- Ruth O’rEganRORuth O’rEgan
- 1 April 2014
- journal article
- Published by Elsevier in Patient Education and Counseling
- Vol. 95 (1) , 98-103
Abstract
No abstract availableKeywords
Funding Information
- Avon Foundation Breast Cancer Crusade
This publication has 38 references indexed in Scilit:
- Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider–patient communicationBreast Cancer Research and Treatment, 2012
- Compliance and persistence of endocrine adjuvant breast cancer therapyBreast Cancer Research and Treatment, 2011
- Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer PatientsJournal of Clinical Oncology, 2010
- Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapyCritical Reviews in Oncology/Hematology, 2010
- Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancerBritish Journal of Cancer, 2008
- A large-scale validation study of the Medication Adherence Rating Scale (MARS)Schizophrenia Research, 2008
- Adherence to medication in bipolar disorder: a qualitative study exploring the role of patients’ beliefs about the condition and its treatmentBipolar Disorders, 2007
- Adherence to tamoxifen over the five-year courseBreast Cancer Research and Treatment, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986